Techno Drugs Statistics
Total Valuation
Techno Drugs has a market cap or net worth of BDT 3.83 billion. The enterprise value is 6.12 billion.
Market Cap | 3.83B |
Enterprise Value | 6.12B |
Important Dates
The next estimated earnings date is Thursday, September 25, 2025.
Earnings Date | Sep 25, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Techno Drugs has 132.00 million shares outstanding. The number of shares has increased by 31.22% in one year.
Current Share Class | 132.00M |
Shares Outstanding | 132.00M |
Shares Change (YoY) | +31.22% |
Shares Change (QoQ) | +0.37% |
Owned by Insiders (%) | 66.79% |
Owned by Institutions (%) | n/a |
Float | 37.84M |
Valuation Ratios
The trailing PE ratio is 16.09.
PE Ratio | 16.09 |
Forward PE | n/a |
PS Ratio | 1.22 |
PB Ratio | 0.96 |
P/TBV Ratio | 0.96 |
P/FCF Ratio | n/a |
P/OCF Ratio | 22.39 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.42, with an EV/FCF ratio of -9.98.
EV / Earnings | 27.47 |
EV / Sales | 1.96 |
EV / EBITDA | 6.42 |
EV / EBIT | 10.59 |
EV / FCF | -9.98 |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.68.
Current Ratio | 2.17 |
Quick Ratio | 1.02 |
Debt / Equity | 0.68 |
Debt / EBITDA | 2.83 |
Debt / FCF | -4.40 |
Interest Coverage | 1.76 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | 10.06% |
Revenue Per Employee | 1.85M |
Profits Per Employee | 131,467 |
Employee Count | 1,694 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Techno Drugs has paid 27.56 million in taxes.
Income Tax | 27.56M |
Effective Tax Rate | 11.01% |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 27.58 |
200-Day Moving Average | 35.09 |
Relative Strength Index (RSI) | 60.67 |
Average Volume (20 Days) | 528,504 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Techno Drugs had revenue of BDT 3.13 billion and earned 222.71 million in profits. Earnings per share was 1.80.
Revenue | 3.13B |
Gross Profit | 1.30B |
Operating Income | 577.51M |
Pretax Income | 250.26M |
Net Income | 222.71M |
EBITDA | 925.89M |
EBIT | 577.51M |
Earnings Per Share (EPS) | 1.80 |
Balance Sheet
The company has 405.40 million in cash and 2.69 billion in debt, giving a net cash position of -2.29 billion or -17.34 per share.
Cash & Cash Equivalents | 405.40M |
Total Debt | 2.69B |
Net Cash | -2.29B |
Net Cash Per Share | -17.34 |
Equity (Book Value) | 3.99B |
Book Value Per Share | 30.24 |
Working Capital | 1.85B |
Cash Flow
In the last 12 months, operating cash flow was 170.98 million and capital expenditures -783.71 million, giving a free cash flow of -612.73 million.
Operating Cash Flow | 170.98M |
Capital Expenditures | -783.71M |
Free Cash Flow | -612.73M |
FCF Per Share | -4.64 |
Margins
Gross margin is 41.50%, with operating and profit margins of 18.47% and 7.12%.
Gross Margin | 41.50% |
Operating Margin | 18.47% |
Pretax Margin | 8.00% |
Profit Margin | 7.12% |
EBITDA Margin | 29.61% |
EBIT Margin | 18.47% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.20, which amounts to a dividend yield of 4.14%.
Dividend Per Share | 1.20 |
Dividend Yield | 4.14% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | 22.18% |
Buyback Yield | -31.22% |
Shareholder Yield | -27.08% |
Earnings Yield | 5.82% |
FCF Yield | -16.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Techno Drugs has an Altman Z-Score of 2.09 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.09 |
Piotroski F-Score | 3 |